(New York, NY) – June 16, 2014 – AiCure, an artificial intelligence company providing advanced facial recognition solutions to monitor medication adherence, is in the final stages of completing a Phase II schizophrenia study for a top-ten pharmaceutical company. AiCure’s medication adherence platform, AiViewTM, was selected to be implemented in the trial in order to accurately and remotely track participant adherence throughout the study. The US-based study enrolled 52 patients over 180 days. Preliminary data showed AiViewTMwas successfully used by a majority of participants in the multi-site trials for up to six months. Average medication adherence rates were better than expected – 80% or above – and data over time confirmed that early behavior was strongly predictive of future behavior. The AiViewTM platform also allowed the sponsor to identify non-adherence and confirm deliberate non-adherence / duplicate enrollment within the first three weeks. While presenting the data at the ASCP (American Society of Clinical Psychopharmacology) on June 16th, Adam Hanina, CEO, demonstrated how early patient categorization and predictive algorithms based on visual confirmation of medication administration can be used in future trial design to minimize risk and improve efficiencies across the drug development pipeline.